SINTX Technologies Names New President

SINTX Technologies Inc. has welcomed a new leader to its top management team, appointing Ryan Elmore as president.

Elmore most recently served as core business director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical device commercialization, he is well-versed in building go-to-market strategies, developing strategic accounts, and scaling revenue through partner-driven commercialization.

“Ryan is a proven commercial leader, and his appointment represents an important step as we continue to advance SINTX’s evolution into a platform company,” SINTX Technologies Chairman/CEO Eric K. Olson said. “SINTX is positioned at the intersection of advanced ceramics, polymer composites, and biomaterials. We believe our opportunity may extend well beyond implants. Our priority is to convert our materials science and IP into measurable commercial traction through licensing, strategic partnerships, and expanded partnership engagement.”

Elmore will be responsible for executing SINTX’s business and operational strategy as the company accelerates its evolution from a product-focused medical device manufacturer to a broader biomaterials platform company. This strategy is supported by SINTX’s proprietary implantable-grade silicon nitride expertise and expanding intellectual property portfolio, including method and composition patents related to SiNERGY SiN/PEEK biocomposites and antipathogenic fibrous material technologies. SINTX believes these platforms may enable multiple commercial pathways across implantable and non-implantable medical applications.

In addition to expanding adoption of SiNERGY SiN/PEEK, Elmore will lead commercialization through business development efforts to advance silicon nitride technologies under evaluation in new product categories, including sutures, mesh, wound dressings, and other textile-based applications. The company is also expanding its capabilities to support multiple material forms—including 3D-printable filament, extruded rod, and sheet stock—to simplify evaluation, qualification, and adoption by contract manufacturers, and strategic partners across various manufacturing workflows.

“Ryan’s mandate is clear: implement a disciplined commercial execution strategy that translates our platform assets into scalable revenue opportunities,” Olson stated. “That includes expanding SiNERGY SiN/PEEK into filament, rod, and sheet formats to support both subtractive and AI-assisted 3D manufacturing workflows, while accelerating business development in silicon nitride applications that extend beyond traditional medical device categories.”

Elmore will work closely with the company’s manufacturing, quality, regulatory, and R&D teams to support product development, regulatory compliance, and business development initiatives, including potential distribution, licensing, and strategic partnership opportunities.

“I am excited to join SINTX at a defining moment in its evolution,” Elmore commented. “SINTX has built a differentiated platform around silicon nitride biomaterials, supported by deep materials science expertise, a strong intellectual property foundation, and U.S.-based manufacturing. My focus will be to execute a commercial strategy aimed at supporting market engagement across multiple verticals—from SiNERGY SiN/PEEK biocomposites for next-generation implants, to antipathogenic fibrous material applications for sutures, mesh, and wound dressings. We believe these technologies have the potential to address meaningful clinical needs, and we intend to build momentum through disciplined execution, quality, and service.”

Headquartered in Salt Lake City, SINTX Technologies Inc. is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. With thousands of medical devices implanted since 2008 and nearly two decades of peer-reviewed research, SINTX considers itself a leader in high-performance biomaterials that enhance clinical outcomes and patient safety. Supported by a strong patent portfolio, U.S.-based manufacturing, and strategic industry partnerships, the company continues to expand its technology platform through innovation and market diversification, including the U.S. Food and Drug Administration-cleared SINAPTIC Foot and Ankle Implant System for reconstructive surgery.